Dergiler / Nöropsikiyatri Arşivi / 2020 / Cilt: 57 - Sayı: 3

The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation

Selektif Amigdalohipokampektomi Operasyonu Geçiren Mezial Temporal Lob Epilepsili Hastaların Klinik-Patolojik Özellikleri ile Hipokampal Sklerozda p-Glikoprotein Ekspresyonu İlişkisi

Sayfa
204–209
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In patients with HS-MTLE, potential use of the p-gp inhibitors as additional therapy and developing novel drugs not carried by multidrug carriers expressed in blood-brain barrier should be regarded as the new treatment targets.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: The overproduction of the efflux transporters in the bloodbrain barrier is considered to play a role in the development of drug resistance in mesial temporal lobe epilepsy (MTLE) patients.
📊
Temel Bulgular & Veri:Methods: This study included a total of 33 patients who underwent selective amygdala-hippocampectomy operation.
💡
Sonuç & Katkı:In patients with HS-MTLE, potential use of the p-gp inhibitors as additional therapy and developing novel drugs not carried by multidrug carriers expressed in blood-brain barrier should be regarded as the new treatment targets.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Introduction: The overproduction of the efflux transporters in the bloodbrain barrier is considered to play a role in the development of drug resistance in mesial temporal lobe epilepsy (MTLE) patients. The aim of the present study was to investigate the relationship of clinical features of patients with MTLE accompanied by hippocampal sclerosis (HS) and the p-glycoprotein (p-gp) expression and neuronal loss in the hippocampus. Methods: This study included a total of 33 patients who underwent selective amygdala-hippocampectomy operation. A detailed medical history of each patient, including age, side of HS, sex, age of habitual seizure onset, duration of habitual seizures, type and age of initial precipitating injury, presence and duration of latent period, presence and duration of silent period, monthly seizure frequency within 1 year prior to operation, mean age at the time of operation was evaluated retrospectively. Results: The p-gp expression was significantly higher in the patient group with a seizure frequency of more than 15 days per month and a disease duration of more than 20 years. There was no significant difference between the p-gp expression and the clinical features of the MTLE-HS patients. Conclusion: These results suggest that p-gp expression is affected by disease duration and seizure frequency rather than a patient’s clinical and pathological properties. In patients with HS-MTLE, potential use of the p-gp inhibitors as additional therapy and developing novel drugs not carried by multidrug carriers expressed in blood-brain barrier should be regarded as the new treatment targets.

Abstract

Amaç: Kan beyin bariyerinde “efflux transporter”ların aşırı üretiminin mezial temporal lob epilepsili (MTLE) hastalarda ilaç tedavisine direnç gelişiminde rol oynayabileceği düşünülmektedir. Bu çalışmada, hipokampal sklerozun (HS) eşlik ettiği MTLE’li hastaların klinik özellikleri ile hipokampusta p-glikoprotein (p-gp) ekspresyonu ve nöronal kayıp arasındaki ilişkiyi araştırmak amaçlanmaktadır. Yöntem: Selektif amigdala-hipokampektomi operasyonu geçirmiş 33 hasta çalışmaya alındı. Her hastanın yaş, HS’nin bulunduğu taraf, cinsiyet, habitüel nöbetlerin başladığı yaş, habitüel nöbetlerin süresi, IPI’nin tipi ve geliştiği yaş, “latent period” varlığı ve süresi, “silent period” varlığı ve süresi, operasyon öncesindeki bir yıl içinde aylık ortalama nöbet frekansı ve operasyonun yapıldığı yaşın ortalaması içeren ayrıntılı klinik hikâyesi retrospektif olarak incelendi. Bulgular: P-gp ekspresyonu ayda 15 günden fazla nöbet sıklığı ve 20 yıldan fazla hastalık süresi olan hasta grubunda anlamlı olarak daha fazla idi. MTLE-HS hastalarının klinik özellikleri ve p-gp ekspresyonu arasında anlamlı bir fark yoktu. Sonuç: Bu bulgular p-gp ekspresyonunun hastanın klinik ve patolojik özelliklerinden çok hastalığın süresi ve nöbet sıklığından etkilendiğini düşündürmektedir. HS-MTLE hastalarında, inhibitörlerin ek tedavi olarak olası kullanımı ve kan beyin bariyerinde eksprese edilen “multi-drug” taşıyıcıları ile taşınmayan ilaçların geliştirilmesi yeni tedavi hedefleri olarak değerlendirilmelidir.

🔖

Bu Makaleye Atıf Yap

ETHEMOĞLU, Ö. U., KAYRAK, N., BİLGİÇ, B., GÜL, G., KUŞÇU, D. Y., KIRBAŞ, D. (2020). The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. Nöropsikiyatri Arşivi, Cilt: 57 - Sayı: 3, 204–209. https://ajindex.com/articles/292790

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Bianchin MM, Velasco TR, Wichert-Ana L, Dos Santos AC, Sakamoto AC. Understanding the association of neurocysticercosis and mesial temporal lobe epilepsy and its impact on the surgical treatment of patients with drugresistant epilepsy. Epilepsy Behav 2017;76:168–177. [CrossRef] 2. Kim WJ, Park SC, Lee SJ, Lee JH, Kim JY, Lee BI, Kim DI. The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999;40:290–293. [CrossRef] 3. Malmgren K, Thom M. Hippocampal sclerosis-origins and imaging. Epilepsia 2012;53(Suppl 4):19–33. [CrossRef] 4. Wieser HG; ILAE Commission on Neurosurgery of Epilepsy. ILAE Commision Report, Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis. Epilepsia 2004;45:695–714. [CrossRef] 5. Arzimanoglou A, Aldenkamp A, Cross H, Lassonde M, Moshé S, Schmitz B. Cognitive dysfunction in children with temporal lobe epilepsy. Paris; John Libbey Eurotext; 2005. 6. Mathern GW, Pretorius JK, Babb TL. Influence of the type of initial precipitating injury and at what age it occurs on course and outcome in patients with temporal lobe seizures. J Neurosurg 1995;82:220–227. [CrossRef] 7. Spector R. Drug Transport in the mammalian central nervous system: multiple complex systems. A critical analysis and commentary. Pharmacology 2000;60:58–73. [CrossRef] 8. Abbott NJ, Khan EU, Rollinson CMS, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ. Drug resistance in epilepsy: the role of the bloodbrain barrier. In: Ling V, editor. Mechanisms of drug resistance in epilepsy. Lessons from Oncology. Chichester: Wiley, Ltd.; 2002. pp.38–47. 9. Weidner LD, Kannan P, Mitsios N, Kang SJ, Hall MD, Theodore WH, Innis RB, Mulder J. The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue. Epilepsia 2018;59:1507–1517. [CrossRef] 10. Kubota H, Ishihara H, Langmann T, Schmitz G, Stieger B, Wieser HG, Yonekawa Y, Frei K. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006;68:213–228. [CrossRef] 11. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011;365:919–926. [CrossRef] 12. Wyler AR, Dohan FC, Schweitzer JB, Berry AD. A Grading System for Mesial Temporal Pathology (Hippocampal Sclerosis) from Anterior Temporal Lobectomy. J Epilepsy 1992;5:220–225